Biogen Stock News

Aduhelm works by removing sticky deposits of a protein called amyloid beta from the brains of patients in earlier stages of Alzheimer''s in order to stave off its ravages.

(RTTNews) - Biogen Inc. (BIIB), an American company focused on the therapies for the treatment of neurological diseases said it intends to seek re-examination of negative opinion adopted by European Medicines Agency or EMA for the company''s Alzheimer''s drug aducanumab. EMA''s Committee for Medicinal Products for Human Use (CHMP) opted for a

Biogen Inc. and partner Eisai Co. Ltd said Friday an advisory committee to the European Medicines Agency has adopted a negative opinion on its Alzheimer''s treatment aducanumab, known as aduhelm in the U.S. The company was seeking an authorization for the treatment in patients in the early stages of the disease known as mild cognitive impairment. "This decision is aligned to the negative trend vote of the committee in November 2021. Biogen will seek a re-examination of the opinion by the CHMP," said Biogen, referring to the Committee for Medicinal Products for Human Use. Biogen shares slid 3% premarket on the news. The drug has been approved by the U.S. Food and Drug Administration but that decision was viewed as controversial. Biogen in July requested a narrower indication -- the initial approval was for all people with the disease. Several members of the FDA''s advisory committee that voted against the agency approving aduhelm quit in response, and acting FDA commissioner Janet Woodcock in July announced a federal investigation into the approval process.

Biogen to seek re-examination following CHMP negative opinion for aducanumabCAMBRIDGE, Mass., Dec. 17, 2021Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the Committee

Biogen to seek re-examination following CHMP negative opinion for aducanumab Biogen to seek re-examination following CHMP negative opinion for aducanumab

Biogen (BIIB) expects to start the phase IV post-marketing confirmatory study of Aduhelm for Alzheimer's disease in 2022. It expects to complete the study in four years from the study initiation date.

Biogen and its partner Eisai Co said they would seek a re-examination of the opinion given by the European Medicines Agency.

The stock price of Biogen Inc (NASDAQ: BIIB) fell by over 2.9% pre-market today. This is why it happened.

Biogen Inc. BIIB, -0.15% and partner Eisai Co. Ltd ESALY, +1.13% 4523, -2.11% said Friday an advisory committee to the European Medicines Agency has adopted a negative opinion on its Alzheimer's treat

Biogen's Alzheimer's drug Aduhelm was approved for sale by the FDA in June. But whether or not it actually works is another question entirely.

Biogen Inc. (BIIB) closed the most recent trading day at $235.52, moving -0.15% from the previous trading session.

Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) are looking to get initial data from the FDA-mandated confirmatory trial for its Alzheimer's disease drug Aduhelm out in four years.  The

The study will enroll more than 1,300 patients with early-stage Alzheimers from the U.S. and internationally, the company said.

Shares of Biogen Inc. BIIB, +2.22% gained 0.9% in premarket trading on Thursday after the company said it plans to submit a protocol for a Phase 4 confirmatory study for its Alzheimer's disease drug t